Immunomodulatory fusion proteins to treat solid malignancies.

Immunotherapies are transforming conventional cancer treatments with significant improvement of patient survival rates. FDA-approved immunotherapies (immune checkpoint inhibitors, ICIs) have shown remarkable success in the treatment of hematologic malignancies but very low response rate in patients with solid tumors. Therefore, there is an urgent need for novel therapies against solid malignancies. Cura Therapeutics is developing innovative immunotherapies to cure solid malignancies and infectious diseases. Our immunotherapy platform simultaneously activates the immune response against cancer while disrupting the tumor blood supply. Our immunotherapies also induce an immunological memory that prevent cancer recurrence. Currently, there are no treatments on the market or in clinical trials that combine these properties in one single therapy. Our immunotherapy platform can be applied as a stand-alone treatments or in combination with ICIs, CAR T cells and chemotherapies (for cancer).

Faculty Supervisor:

Michel Tremblay

Student:

Chuhan Feng

Partner:

District 3 Innovation Center

Discipline:

Biology

Sector:

Professional, scientific and technical services

University:

McGill University